FBIO trades 81.2% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FBIO achieves its forward estimates and maintains a stable P/E multiple of 1.1x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Fortress Biotech, Inc. (FBIO) has a Wall Street consensus price target of $5.00, based on estimates from 6 covering analysts. With the stock currently trading at $2.76, this represents a potential upside of +81.2%. The company has a market capitalization of $106M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, FBIO trades at a trailing P/E of -40.9x and forward P/E of 1.1x. Analysts expect EPS to grow -27.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $0.38, with bear and bull scenarios of $0.24 and $0.50 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
XOMAXOMA Royalty Corp. | $529M | $42.15 | $44.50 | +5.6% | Buy | 53.7x | 10 |
RCUSArcus Biosciences, Inc. | $3.1B | $31.00 | $31.00 | +0.0% | Buy | — | 18 |
ROIVRoivant Sciences Ltd. | $24.5B | $34.07 | $37.17 | +9.1% | Buy | — | 15 |
MNOVMediciNova, Inc. | $63M | $1.29 | — | — | — | — | — |
AVXLAnavex Life Sciences Corp. | $243M | $2.62 | $11.00 | +319.8% | Buy | — | 13 |
CASICASI Pharmaceuticals, Inc. | $2M | $0.15 | — | — | — | — | — |
NUVBNuvation Bio Inc. | $2.0B | $5.65 | $13.00 | +130.1% | Buy | — | 9 |
AGIOAgios Pharmaceuticals, Inc. | $2.3B | $37.90 | $45.00 | +18.7% | Buy | — | 29 |
ABBVAbbVie Inc. | $444.4B | $251.52 | $258.00 | +2.6% | Buy | 17.7x | 41 |
PFEPfizer Inc. | $138.1B | $24.29 | $26.75 | +10.2% | Hold | 8.2x | 39 |
Quick answers to the most common questions about buying FBIO stock.
The consensus Wall Street price target for FBIO is $5, representing 81.2% upside from the current price of $2.76. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
FBIO has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 81.2% upside from current levels.
With a forward P/E of 1.15x, FBIO trades at a relatively low valuation. The consensus target of $5 implies 81.2% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $5 for FBIO, while the most conservative target is $5. The consensus of $5 represents the median expectation. Our quantitative valuation model projects a bull case target of $1 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
FBIO is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FBIO stock forecast based on 6 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $0, with bear/bull scenarios of $0/$1.
Our quantitative valuation model calculates FBIO's fair value at $0 (base case), with a bear case of $0 and bull case of $1. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
FBIO trades at a forward P/E ratio of 1.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on FBIO, with a "Buy" consensus rating and $5 price target (81.2% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FBIO analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground. Our model's $0-$1 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.